<DOC>
	<DOC>NCT01240759</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of S-707106 co-administered with metformin in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy</brief_title>
	<detailed_description>Based on the unmet clinical need for more safe and effective type 2 diabetes mellitus therapies, together with the nonclinical efficacy and safety profile of S-707106, Shionogi USA, Inc. is initiating studies to further assess the efficacy, clinical pharmacology and safety profile of S-707106 in preparation for full clinical development as a novel treatment for type 2 diabetes mellitus. It is anticipated that S-707106 will provide clinicians and patients with a new therapeutic option to treat type 2 diabetes mellitus with potential advantages over existing therapy.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Main Subjects with type 2 diabetes mellitus receiving a stable dose of metformin for the past 3 months (with no other medication for glycemic control) and who are clinically stable as determined by medical history Body mass index (BMI) ≥25.0 and &lt;45.0 (kg/m2) using http://www.bmicalculator.org/ as the BMI calculator No clinically significant abnormal laboratory tests as determined by the investigator except Hemoglobin A1c level ≥7.5% and ≤11.0% and C peptide level &gt;1.0 ng/mL Main Type 1 diabetes mellitus or gestational diabetes mellitus within last 6 months Use of any medication for glycemic control other than metformin during the past 3 months or thiazolidinediones within the past year Congestive heart failure as defined by New York Heart Association class III or IV Fasting glucose &gt;270 mg/dL Creatinine clearance is &lt;60 mL/minute History of myocardial infarction within the past 3 months, history of clinically significant cardiac arrhythmia, clinically significant hypotension or hypertension, or clinically significant abnormal electrocardiogram as determined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Metformin</keyword>
</DOC>